Oramed Pharmaceuticals Inc., of Jerusalem, received a $3 million milestone payment from Hefei Tianhui Incubator of Technologies Co. Ltd., of Hefei, China, in association with the licensing deal for Oramed's orally ingestible insulin capsule (ORMD-0801) in greater China.